SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-015041
Filing Date
2024-04-17
Accepted
2024-04-17 16:30:44
Documents
13
Period of Report
2024-04-17
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 46272
  Complete submission text file 0001493152-24-015041.txt   221955

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE zvsa-20240417.xsd EX-101.SCH 3012
3 XBRL LABEL FILE zvsa-20240417_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE zvsa-20240417_pre.xml EX-101.PRE 22357
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3783
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

IRS No.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41184 | Film No.: 24851468
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)